Baker Bros. Advisors Reduces $5M in Fate Therapeutics, Inc. ($FATE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors reduced its position in Fate Therapeutics, Inc. ($FATE), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Fate Therapeutics, Inc. after selling 2,485,018 shares during the quarter.
Fate Therapeutics, Inc. Stock Down 18.9%
Shares of Fate Therapeutics, Inc. ($FATE) traded around $1.97 on Saturday, down 18.9% for the day.
Fate Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Get Fate Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FATE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.